Precise Treatment in Hepatobiliary Cancers (PTHBC)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-12-31

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to explore the precise treatment in hepatobiliary cancer patients and evaluate drug safety, progression free and overall survival. This trial study is based on genetic tests, then therapeutic target drugs are administered according to the genetic test reports. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit from precise treatment which targets particular genetic abnormality. The identifications of these genetic abnormalities may help treat hepatobiliary cancer patients better.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing

NCT05520788

Hepatocellular Carcinoma Biliary Tract Cancer

RECRUITING

Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors

NCT03895970

Liver Neoplasm Malignant Primary Cholangiocarcinoma Combinational Immunotherapy +1 more

COMPLETED PHASE2

Real-world Study for Patients With Advanced Hepatobiliary Tumors

NCT03892577

Objective Response Rate Progression-free Survival Overall Survival +4 more

RECRUITING

Study of GNS561 in Patients With Liver Cancer

NCT03316222

Hepatocellular Carcinoma Cholangiocarcinoma, Intrahepatic

TERMINATED PHASE1/PHASE2

Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

NCT04256980

Cholangiocarcinoma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The genetic tests are performed for the eligible subjects in this study, then therapeutic target drugs are administered according to the genetic test reports. While the precise treatments, follow-ups are conducted to evaluate the efficacy and safety of the target drugs for the subjects, until the overall survival.

Study Type: Non-Interventional. Masking: Open Label.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Neoplasms Biliary Tract Neoplasms Hepatobiliary Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Precise treatment

All patients should accept next-generation sequencing (NGS) test before treatment.

Precise treatment

Intervention Type GENETIC

During screening stage, all patients should accept next-generation sequencing (NGS) test.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Precise treatment

During screening stage, all patients should accept next-generation sequencing (NGS) test.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 18 to 65, male or female.
* Radiologically and pathologically confirmed as hepatobiliary cancers with stage IV.
* Palliative care as the preferred.
* The result of next-generation sequencing (NGS) test show the patient has gene mutation and also can be treated by the right commercial products that have been approved by the China Food and Drug Administration (CFDA) or the Food and Drug Administration (FDA).
* ECOG performance status 0-2.
* Life expectancy ≥3 months.
* Voluntarily participate in the study and agree to sign informed consent form.

Exclusion Criteria

* Hepatobiliary cancer patient with stageI-III, or with any of the following items will not be eligible for screening.Such as, suitable for the treatment of radical resection, radical resection but evaluation unmeasurable.
* The result of NGS test show the patient has no gene mutation, or has gene mutation but no medicine.
* ECOG performance status ≥ 3.
* Female patients who are pregnant or not using a contraceptive method of birth control.
* History or presence of serious cardiovascular or cerebrovascular abnormalities.
* Abnormalities of the hepatic or renal functions, such as jaundice, ascites, bilirubin ≥ 1.5×ULN, alkaline phosphatase ≥ 3×ULN, persistent protein urine≥ grade 3 (according to National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTC-AE\] v4.0), creatinine ratio \> 3.5g/24 hours, renal failure.
* Persistent infection \> grade 2 (according to National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTC-AE\] v4.0).
* Patient has underwent a major operation 4 weeks prior to screening or has not yet recovered from the operation.
* Patient with epilepsy, known or untreated brain metastases.
* The presence of wounds, ulcers or fractures that can not be healed, or with a past history of transplantation.
* The presence of bleeding events ≥grade 3 (according to National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTC-AE\] v4.0) , present evidence or past history of coagulation dysfunction disorders.
* Known human immunodeficiency virus (HIV) infection history.
* Patient with drug abuse or unstable compliance.
* The presence of unresolved toxicity caused by any previous treatment/operation \> grade 1 (according to National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTC-AE\] v4.0), except alopecia, anemia or hypothyroidism).
* Investigator consider that the patient should not be enrolled in this study by careful assessment.
* The subjects participate in any other clinical trial in the meantime.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No